Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$6.8b

Jazz Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Jazz Pharmaceuticals's earnings have been declining at an average annual rate of -26.6%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 15.1% per year. Jazz Pharmaceuticals's return on equity is 10.5%, and it has net margins of 10.1%.

Key information

-26.6%

Earnings growth rate

-28.9%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate15.1%
Return on equity10.5%
Net Margin10.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Revenue & Expenses Breakdown

How Jazz Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:JAZZ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,9103951,359869
31 Mar 243,8433311,361857
31 Dec 233,8344151,307824
30 Sep 233,794801,290782
30 Jun 233,763-871,378685
31 Mar 233,738-1561,397615
31 Dec 223,659-2241,399555
30 Sep 223,584-191,276532
30 Jun 223,481-521,222536
31 Mar 223,300-4501,291530
31 Dec 213,094-3301,399476
30 Sep 212,863-1611,326416
30 Jun 212,626401,170354
31 Mar 212,436518926306
31 Dec 202,364239880310
30 Sep 202,280179846316
30 Jun 202,217133818317
31 Mar 202,188280808295
31 Dec 192,162523762275
30 Sep 192,056609626259
30 Jun 191,988656662230
31 Mar 191,954486586224
31 Dec 181,891447625227
30 Sep 181,851520667234
30 Jun 181,793434578230
31 Mar 181,687447610214
31 Dec 171,619488544198
30 Sep 171,579372518175
30 Jun 171,541399505175
31 Mar 171,528408496174
31 Dec 161,488397480160
30 Sep 161,432363470148
30 Jun 161,399361462151
31 Mar 161,352335447139
31 Dec 151,325330433133
30 Sep 151,312328422130
30 Jun 151,278266411102
31 Mar 151,23522239994
31 Dec 141,1735840485
30 Sep 141,0813235074
30 Jun 141,0068232764
31 Mar 149238030553
31 Dec 1387221628142

Quality Earnings: JAZZ has a large one-off loss of $215.1M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: JAZZ became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: JAZZ's earnings have declined by 26.6% per year over the past 5 years.

Accelerating Growth: JAZZ has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: JAZZ has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).


Return on Equity

High ROE: JAZZ's Return on Equity (10.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies